Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Src family kinases control multiple cancer cell properties including cell cycle progression, survival, and metastasis. Recent studies suggest that the Src inhibitor dasatinib blocks these critical cancer cell functions. METHODS: Because the molecular mechanism of action of dasatinib in breast cancers has not been investigated, we evaluated the effects of dasatinib as a single agent and in combination with the commonly used chemotherapeutic doxorubicin, on the proliferation, viability, and invasive capacity of breast cancer cells lines earlier categorised as dasatinib-sensitive (MDA-MB-231) and moderately resistant (MCF7 and T47D). We also tested the effects of these drugs on the actin cytoskeleton and associated signalling pathways. RESULTS: The cell lines tested varied widely in sensitivity to growth inhibition (IC(50)=0.16-12.3 microM), despite comparable Src kinase inhibition by dasatinib (IC(50)=17-37 nM). In the most sensitive cell line, MDA-MB-231, dasatinib treatment induced significant G(1) accumulation with little apoptosis, disrupted cellular morphology, blocked migration, inhibited invasion through Matrigel (P<0.01), and blocked the formation of invadopodia (P<0.001). Importantly, combination treatment with doxorubicin resulted in synergistic growth inhibition in all cell lines and blocked the migration and invasion of the highly metastatic, triple-negative MDA-MB-231 cell line. CONCLUSION: The observed synergy between dasatinib and doxorubicin warrants the re-evaluation of dasatinib as an effective agent in multi-drug regimens for the treatment of invasive breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Structure and regulation of Src family kinases
Boggon, T. J., & Eck, M. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208081 · Cited by 712 · cited 2×
“Recently, Finn et al (2007) demonstrated the selective efficacy of dasatinib in ‘triple-negative’ breast cancer cells, which lack oestrogen receptor, progesterone receptor, and HER2 (Boggon and Eck, 2004).”
BackgroundCopland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635 · cited 2×
“These levels are below the maximal plasma concentrations of dasatinib achieved in Phase I clinical trials, and are therefore clinically relevant (Copland et al, 2006).”
BackgroundActivating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 1×
“Previous studies have examined gene expression arrays to identify potential markers for dasatinib sensitivity and found that caveolin and moesin mRNAs are downregulated in dasatinibsensitive cells after treatment (Finn et al, 2007; Huang et al, 2007).”
BackgroundSelf-citationMao, W., Irby, R., Coppola, D., Fu, L., Wloch, M., Turner, J., Yu, H., Garcia, R., Jove, R., & Yeatman, T. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201496 · Cited by 200 · cited 1×
“Elevated Src activity has been shown to increase growth rate (Mao et al, 1997) and metastatic potential, while inhibiting cell –cell adhesion (Hamaguchi et al, 1993) in human cancers.”
Background
Cited by
Small-molecule–induced DNA damage identifies alternative DNA structures in human genes
Rodriguez, R., Miller, K. M., Forment, J. V., Bradshaw, C. R., Nikan, M., Britton, S., Oelschlaegel, T., Xhemalce, B., Balasubramanian, S., & Jackson, S. P. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.780 · Cited by 741
Lockman, P. R., Mittapalli, R. K., Taskar, K. S., Rudraraju, V., Gril, B., Bohn, K. A., Adkins, C. E., Roberts, A., Thorsheim, H. R., Gaasch, J. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1564 · Cited by 693
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
Zhang, S., & Yu, D. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.11.002 · Cited by 319
Alavi-Tabari, S. A. R., Khalilzadeh, M. A., & Karimi-Maleh, H. (2018) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2018.01.034 · Cited by 305
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
“In triple negative breast cancer (TNBC) cells (4-6), gastric, (7), pancreatic (8), head and neck and lung cell lines (9), or myeloid leukemias (10), dasatinib inhibited cell duplication, causing G0/G1 arrest.”
Metadata
- Authors
- Pichot, C. S., Hartig, S. M., Xia, L., Arvanitis, C., Monisvais, D., Lee, F. Y., Frost, J. A., & Corey, S. J.
- Venue
- British Journal of Cancer
- Published
- 2009-06-09
- Volume
- 101
- Issue
- 1
- Pages
- 38-47
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2032225894
- Cited by
- 173
- References
- 7
- FWCI
- 8.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.